Inhibition of lipoxygenases and cyclooxygenases by linoleyl hydroxamic acid: Comparative in vitro studies

Journal of Lipid Research

Volumn 49, Issue 6, 2008, Pages 1284-1294

  Butovich, Igor A ^a   Lukyanova, Svetlana M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Animal; Anti cancer; Anti inflammatory; Arachidonic acid; Drug discovery; Enzyme inhibition; Human; Linoleic acid

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HYDROXAMIC ACID DERIVATIVE; LINOLEIC ACID; LINOLEYL HYDROXAMIC ACID; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; LINOLEIC ACID HYDROXAMATE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALLERGY; ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; NEOPLASM; NONHUMAN; OXYGENATION; POTATO; PRIORITY JOURNAL; PSORIASIS; RETICULOCYTE; SOYBEAN; STROKE; ANIMAL; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; HUMANS; LINOLEIC ACIDS; LIPOXYGENASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 48549099116     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700602-JLR200     Document Type: Article

References (83)

1. Peters-Golden, M., and T. G. Brock. 2003. 5-Lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids. 69: 99-109.
2. Camp, R. D., A. I. Mallet, P. M. Woollard, S. D. Brain, A. K. Black, and M. W. Greaves. 1983. The identification of hydroxy fatty acids in psoriatic skin. Prostaglandins. 26: 431-447. (Pubitemid 14240769)
3. el Attar, T. M., H. S. Lin, and J. Y. Vanderhoek. 1985. Biosynthesis of prostaglandins and hydroxy fatty acids in primary squamous carcinomas of head and neck in humans. Cancer Lett. 27: 255-259.
4. Kiss, L., H. Schütte, K. Mayer, H. Grimm, W. Padberg, W. Seeger, and F. Grimminger. 2000. Synthesis of arachidonic acid-derived lipoxygenase and cytochrome P450 products in the intact human lung vasculature. Am. J. Respir. Crit. Care Med. 161: 1917-1923.
5. Yue, H., S. A. Jansen, K. I. Strauss, M. R. Borenstein, M. F. Barbe, L. J. Rossi, and E. Murphy. 2007. A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue. J. Pharm. Biomed. Anal. 43: 1122-1134.
6. Salzmann-Reinhardt, U., H. Kühn, R. Wiesner, and S. Rapoport. 1985. Metabolism of polyunsaturated fatty acids by rabbit reticulocytes. Eur. J. Biochem. 153: 189-194.
7. Wiseman, J. S., M. T. Skoog, and C. H. Clapp. 1988. Activity of soybean lipoxygenase in the absence of lipid hydroperoxide. Biochemistry. 27: 8810-8813.
8. Hamberg, M. 1971. Steric analysis of hydroperoxides formed by lipoxygenase oxygenation of linoleic acid. Anal. Biochem. 43: 515-526.
9. Hamberg, M., and B. Samuelsson. 1967. On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J. Biol. Chem. 242: 5329-5335.
10. Galliard, T., and D. R. Phillips. 1971. Lipoxygenase from potato tubers. Partial purification and properties of an enzyme that specifically oxygenates the 9-position of linoleic acid. Biochem. J. 124: 431-438.
11. Butovich, I. A., M. Hamberg, and O. Rådmark. 2005. Novel oxylipins formed from docosahexaenoic acid by potato lipoxygenase - 10(S)- hydroxydocosahexa-enoic acid and 10,20-dihydroxydocosahexaenoic acid. Lipids. 40: 249-257.
12. Butovich, I. A. 2005. On the structure and synthesis of neuroprotectin D1, a novel anti-inflammatory compound of the docosahexaenoic acid family. J. Lipid Res. 46: 2311-2314. (Pubitemid 41532519)
13. Butovich, I. A., S. M. Lukyanova, and C. Bachmann. 2006. Dihydroxydocosahexaenoic acids of the neuroprotectin D family: synthesis, structure, and inhibition of human 5-lipoxygenase. J. Lipid Res. 47: 2462-2474. (Pubitemid 44936108)
14. Shimizu, T., O. Rådmark, and B. Samuelsson. 1984. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc. Natl. Acad. Sci. USA. 81: 689-693.
15. Hombeck, M., G. Pohnert, and W. Boland. 1999. Biosynthesis of dictyopterene A: stereoselectivity of a lipoxygenase/hydroperoxide lyase from Gomphonema parvulum (Bacillariophyceae). Chem. Commun. 3: 243-244. (Pubitemid 29080284)
16. Sloane, D. L., M. F. Browner, Z. Dauter, K. Wilson, R. J. Fletterick, and E. Segal. 1990. Purification and crystallization of 15-lipoxygenase from rabbit reticulocytes. Biochem. Biophys. Res. Commun. 173: 507-513.
17. Phillis, J. W., L. A. Horrocks, and A. A. Farooqui. 2006. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Brain Res. Rev. 52: 201-243.
18. Fürstenberger, G., P. Krieg, K. Müller-Decker, and A. J. Habenicht. 2006. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int. J. Cancer. 119: 2247-2254. (Pubitemid 44546942)
19. Jatana, M., S. Giri, M. A. Ansari, C. Elango, A. K. Singh, I. Singh, and M. Khan. 2006. Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J. Neuroinflammation. 11: 3-12. (Pubitemid 44192728)
20. Rossoni, G., A. Sala, F. Berti, T. Testa, C. Buccellati, C. Molta, R. Muller-Peddinghaus, J. Maclouf, and G. C. Folco. 1996. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 276: 335-341.
21. van Leyen, K., H. Y. Kim, S. R. Lee, G. Jin, K. Arai, and E. H. Lo. 2006. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke. 37: 3014-3018.
22. Rubin, P., and K. W. Mollison. 2007. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat. 83: 188-197. (Pubitemid 46661257)
23. Chu, L. S., S. H. Fang, Y. Zhou, G. L. Yu, M. L. Wang, W. P. Zhang, and E. Q. Wei. 2007. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol. Sin. 28: 763-772.
24. Klickstein, L. B., C. Shapleigh, and E. J. Goetzl. 1980. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. 66: 1166-1170.
25. Araico, A., M. C. Terencio, M. J. Alcaraz, J. N. Domínguez, C. León, and M. L. Ferrándiz. 2007. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5- lipoxygenase inhibitor. Life Sci. 80: 2108-2117. (Pubitemid 46755328)
26. Burka, J. F., and N. A. Paterson. 1980. Evidence for lipoxygenase pathway involvement in allergic tracheal contraction. Prostaglandins. 19: 499-515. (Pubitemid 10070943)
27. Berger, W., M. T. De Chandt, and C. B. Cairns. 2007. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61: 663-676.
28. Steele, V. E., C. A. Holmes, E. T. Hawk, L. Kopelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff. 1999. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 8: 467-483.
29. Steinhilber, D. 1999. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr. Med. Chem. 6: 71-85.
30. Federico, A., F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio. 2007. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer. 121: 2381-2386.
31. Butovich, I. A., V. P. Bridnya, and V. P. Kukhar. 1990. Linoleylhydroxamic acid - a suicide inhibitor of lipoxygenase. Biochemistry-Moscow. 55: 908-912.
32. Butovich, I. A., O. V. Kharchenko, L. B. Bondarenko, V. M. Babenko, and L. Livarchuk. 1994. Linoleyl hydroxamate as 5-lipoxygenase inhibitor. Biochemistry-Moscow. 59: 597-600.
33. Butovich, I. A., and C. C. Reddy. 2002. Inhibition of potato lipoxygenase by linoleyl hydroxamic acid: kinetic and EPR spectral evidence for a two-step reaction. Biochem. J. 365: 865-871. (Pubitemid 34864471)
34. Kharchenko, O. V., V. N. Cernjuk, and I. A. Butovich. 1999. Inhibitory effect of linoleyl-hydroxamic acid on the oxidation of linoleic acid by 12-lipoxygenase from porcine leukocytes. Ukr. Biokhim. Zh. 71: 33-37.
35. Brodowsky, I. D., M. Hamberg, and E. H. Oliw. 1994. BW A4C and other hydroxamic acids are potent inhibitors of linoleic acid 8R-dioxygenase of the fungus Gaeumannomyces graminis. Eur. J. Pharmacol. 254: 43-47.
36. Moibenko, A. A., L. A. Grabovskii, V. N. Kotsiuruba, V. N. Bulakh, L. V. Tumanovskaia, V. I. Azarov, and I. A. Butovich. 1994. The mechanisms of the changes in coronary vascular resistance in anaphylactic shock. Fiziol. Zh. Im. I M Sechenova. 80: 77-82.
37. Kukoba, T. V., M. M. Seredenko, I. A. Butovych, and O. O. Moibenko. 1998. The effect of linoleyl hydroxamic acid on lipid peroxidation processes and on the enzymatic activity of the antioxidant system in rats under hypoxia. Fiziol. Zh. 44: 43-48.
38. Marchenko, H. I., V. M. Kotsiuruba, I. A. Butovych, A. E. Sorochynskyi, V. K. Zrazhevs'ka, and L. V. Tumanovs'ka. 1994. The correction of disorders in arachidonic acid metabolism in coronary spasm of an immune origin. Fiziol. Zh. 40: 81-87.
39. Chobot'ko, H. M. 1998. Effects of modifications of lipoproteins by water soluble forms of lineoleic-hydroxamic acid on biochemical markers of development of atherosclerosis. Ukr. Biokhim. Zh. 70: 64-68.
40. Agrawal, Y. K. 1979. Hydroxamic acids and their metal complexes. Russ. Chem. Rev. 48: 948-963.
41. Hammarberg, T., Y. Y. Zhang, B. Lind, O. Radmark, and B. Samuelsson. 1995. Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase. Eur. J. Biochem. 230: 401-407.
42. Butovich, I. A., V. P. Kukhar, V. P. Bridnya, O. A. Radchenko, and A. Kotlinskaya. 1989. Polyfluorosubstituted alcadiynoic carboxylic and hydroxamic acids as new inhibitors of lipoxygenases. Proc. Natl. Acad. Sci. of Ukraine, ser. B. 5: 55-58.
43. Thorén, S., R. Weinander, S. Saha, C. Jegerschöld, P. L. Pettersson, B. Samuelsson, H. Hebert, M. Hamberg, R. Morgenstern, and P. J. Jakobsson. 2003. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J. Biol. Chem. 278: 22199-22209.
44. Pettersson, P. L., S. Thorén, and P. J. Jakobsson. 2005. Human microsomal prostaglandin E synthase 1: a member of the MAPEG protein superfamily. Methods Enzymol. 401: 147-161. (Pubitemid 43052391)
45. Gibian, M. J., and P. Vandenberg. 1987. Product yield in oxygenation of linoleate by soybean lipoxygenase: the value of the molar extinction coefficient in the spectrophotometric assay. Anal. Biochem. 163: 343-349.
46. Butovich, I. A., E. Uchiyama, and J. P. McCulley. 2007. Lipids of human meibum: mass-spectrometric analysis and structural elucidation. J. Lipid Res. 48: 2220-2235. (Pubitemid 47529564)
47. Aursand, M., and H. Grasdalen. 1992. Interpretation of the 13C-NMR spectra of omega-3 fatty acids extracted from the white muscle of Atlantic salmon (Salmo salar). Chem. Phys. Lipids. 62: 239-251.
48. Gunstone, F. D. 1993. High resolution of 13C-NMR spectroscopy of lipids. In Advances in Lipid Methodology, Vol.2. W. W. Christie, editor. Oily Press, Dundee. 1-68.
49. Jame, A. J., P. M. Lackie, A. M. Cazaly, I. Sayers, J. F. Penrose, S. T. Holgate, and A. P. Sampson. 2007. Human bronchial epithelial cells express an active and inducible biosynthetic pathway for leukotrienes B4 and C4. Clin. Exp. Allergy. 37: 880-892.
50. Farooqui, A. A., L. A. Horrocks, and T. Farooqui. 2007. Modulation of inflammation in brain: a matter of fat. J. Neurochem. 101: 577-599. (Pubitemid 46633316)
51. Takase, B., A. Kurita, T. Maruyama, A. Uehata, T. Nishioka, K. Mizuno, H. Nakamura, K. Katsura, and Y. Kanda. 1996. Change of plasma leukotriene C4 during myocardial ischemia in humans. Clin. Cardiol. 19: 198-204.
52. Adamek, A., S. Jung, C. Dienesch, M. Laser, G. Ertl, J. Bauersachs, and S. Frantz. 2007. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur. J. Pharmacol. 571: 51-54.
53. Goossens, L., N. Pommery, and J. P. Hénichart. 2007. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr. Top. Med. Chem. 7: 283-296.
54. Butovich, I. A., O. V. Harchenko, and V. M. Babenko. 1995. On the interfacial phenomena in lipoxygenase catalysis. Adv. Prostaglandin Thromboxane Leukot. Res. 23: 159-161.
55. Chen, F. L., X. Z. Wang, J. Y. Li, J. P. Yu, C. Y. Huang, and Z. X. Chen. 2008. 12-Lipoxygenase induces apoptosis of human gastric cancer AGS cells via the ERK1/2 signal pathway. Dig. Dis. Sci. 53: 181-187.
56. Fürstenberger, G., P. Krieg, K. Müller-Decker, and A. J. Habenicht. 2006. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int. J. Cancer. 119: 2247-2254. (Pubitemid 44546942)
57. Nie, D., S. Krishnamoorthy, R. Jin, K. Tang, Y. Chen, Y. Qiao, A. Zacharek, Y. Guo, J. Milanini, G. Pages, et al. 2006. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J. Biol. Chem. 281: 18601-18609.
58. Huo, Y., L. Zhao, M. C. Hyman, P. Shashkin, B. L. Harry, T. Burcin, S. B. Forlow, M. A. Stark, D. F. Smith, S. Clarke, et al. 2004. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 110: 2024-2031. (Pubitemid 39331917)
59. Zhao, L., D. Praticò, D. J. Rader, and C. D. Funk. 2005. 12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat. 78: 185-193. (Pubitemid 41636842)
60. Takahashi, Y., H. Zhu, and T. Yoshimoto. 2005. Essential roles of lipoxygenases in LDL oxidation and development of atherosclerosis. Antioxid. Redox Signal. 7: 425-431.
61. Quintana, L. F., B. Guzmán, S. Collado, J. Clària, and E. A. Poch. 2006. A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. Kidney Int. 69: 526-530. (Pubitemid 43164445)
62. Hao, C. M., and M. D. Breyer. 2007. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 71: 1105-1115. (Pubitemid 46809137)
63. Musiek, E. S., R. S. Breeding, G. L. Milne, G. Zanoni, J. D. Morrow, and B. McLaughlin. 2006. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J. Neurochem. 97: 1301-1313. (Pubitemid 43725570)
64. Khanna, S., S. Roy, A. Slivka, T. K. Craft, S. Chaki, C. Rink, M. A. Notestine, A. C. DeVries, N. L. Parinandi, and C. K. Sen. 2005. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke. 36: 2258-2264. (Pubitemid 41429256)
65. Liu, B., W. A. Khan, Y. A. Hannun, J. Timar, J. D. Taylor, S. Lundy, I. Butovich, and K. V. Honn. 1995. 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc. Natl. Acad. Sci. USA. 92: 9323-9327.
66. Kandouz, M., D. Nie, G. P. Pidgeon, S. Krishnamoorthy, K. R. Maddipati, and K. V. Honn. 2003. Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins Other Lipid Mediat. 71: 189-204. (Pubitemid 36929790)
67. Hammarström, S. 1977. Selective inhibition of platelet n-8 lipoxygenase by 5,8,11-eicosatriynoic acid. Biochim. Biophys. Acta. 487: 517-519.
68. Sekiya, K., H. Okuda, and S. Arichi. 1982. Selective inhibition of platelet lipoxygenase by esculetin. Biochim. Biophys. Acta. 713: 68-72.
69. Deschamps, J. D., V. A. Kenyon, and T. R. Holman. 2006. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg. Med. Chem. 14: 4295-4301.
70. Neichi, T., Y. Koshihara, and S. Murota. 1983. Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim. Biophys. Acta. 753: 130-132.
71. Kitamura, S., T. Iida, K. Shirahata, and H. Kase. 1986. Studies on lipoxygenase inhibitors. I. MY3-469 (3-methoxytropolone), a potent and selective inhibitor of 12-lipoxygenase, produced by Streptoverticillium hadanonense KY11449. J. Antibiot. (Tokyo). 39: 589-593.
72. Honn, K. V., D. G. Tang, I. M. Grossi, C. Renaud, Z. M. Duniec, C. R. Johnson, and C. A. Diglio. 1994. Enhanced endothelial cell retraction mediated by 12(S)-HETE: a proposed mechanism for the role of platelets in tumor cell metastasis. Exp. Cell Res. 210: 1-9.
73. Chinnici, C. M., Y. Yao, T. Ding, C. D. Funk, and D. Praticò. 2005. Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am. J. Pathol. 167: 1371-1377.
74. Praticò, D., V. Zhukareva, Y. Yao, K. Uryu, C. D. Funk, J. A. Lawson, J. Q. Trojanowski, and V. M. Lee. 2004. 12/15-Lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am. J. Pathol. 164: 1655-1662.
75. Sadik, C. D., H. Sies, and T. Schewe. 2003. Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action. Biochem. Pharmacol. 65: 773-781.
76. Walther, M., H. G. Holzhütter, R. J. Kuban, R. Wiesner, J. Rathmann, and H. Kühn. 1999. The inhibition of mammalian 15-lipoxygenases by the anti-inflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol. Pharmacol. 56: 196-203.
77. Müller, A., E. Cadenas, P. Graf, and H. Sies. 1984. A novel biologically active seleno-organic compound. I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (ebselen). Biochem. Pharmacol. 33: 3235-3239.
78. Wendel, A., M. Fausel, H. Safayhi, G. Tiegs, and R. Otter. 1984. A novel biologically active seleno-organic compound. II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem. Pharmacol. 33: 3241-3245.
79. Khanapure, S. P., D. S. Garvey, D. R. Janero, and L. G. Letts. 2007. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem. 7: 311-340.
80. Leone, S., A. Ottani, and A. Bertolini. 2007. Dual acting antiinflammatory drugs. Curr. Top. Med. Chem. 7: 265-275.
81. Cicero, A. F., G. Derosa, and A. Gaddi. 2005. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging. 22: 393-403.
82. Wallace, J. M. 2002. Nutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr. Cancer Ther. 1: 7-37.
83. Burka, J. F., and N. A. Paterson. 1980. Inhibition of antigen-induced release of prostaglandin-like material from guinea-pig trachea by antihistamines FPL55712 and atropine. J. Pharm. Pharmacol. 32: 869-870.